Bintrafusp alfa (M7824), targeting both PD-L1 and TGF-β, has shown efficacy in inhibiting tumor mesenchymalization, reducing PD-L1-dependent immunosuppression, and overcoming chemoresistance in NSCLC (80). This evidence concerns the gene CD274 and non-small cell lung carcinoma.